Novel Drug Review of Approved 2020 Breast Cancer Agents
Oscar E. Freyre
Annually, The Food and Drug Administration’s Center for Drug Evaluation and Research publishes a report containing the latest drugs approved. In this review, the following breast cancer agents; Cerianna™ (fluoroestradiol F-18), Trodelvy (sacituzumab govitecan-hziy), and Tukysa (tucatinib), are evaluated for their drug properties including dosing and administration, absorption, distribution, metabolism, excretion, and adverse effects & warnings. In addition to their pharmacological parameters, review of the National Comprehensive Cancer Network (NCCN) Breast Cancer clinical guidelines assess how these agents may impact current clinical practice.